Anne Thirot Bidault

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

Alix Portal, Simon Pernot, David Tougeron et al. · British Journal of Cancer · 2015 · 187 citations · Full text

Medicine, Oncology, Pharmacology +15

FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort

Lysiane Marthey, António Sá Cunha, Jean‐Frédéric Blanc et al. · Annals of Surgical Oncology · 2014 · 174 citations

Medicine, Oncology, Surgery +11

Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02)

Thomas Aparicio, Sandrine Lavau‐Denès, Jean–Marc Phelip et al. · Annals of Oncology · 2015 · 111 citations · Full text

Medicine, Oncology, Pharmacology +8

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Stefan Kubicka, Richard Greil, Thierry André et al. · Annals of Oncology · 2013 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Folfirinox <i>versus</i> gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study

Nicolas Williet, Angélique Saint, Anne‐Laure Pointet et al. · Therapeutic Advances in Gastroenterology · 2019 · 68 citations · Full text

Medicine, Oncology, Pharmacology +14